COVID-19 vaccine response under scrutiny in blood cancer patients

NCT ID NCT04830046

Completed Knowledge-focused Sponsor: Massachusetts General Hospital Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study looked at whether the COVID-19 vaccine triggers a strong immune response in 146 people with multiple myeloma or Waldenstrom's macroglobulinemia. Researchers measured antibody levels 28 days after the final vaccine dose. The goal was to see if these patients, whose immune systems are compromised, can mount effective protection from the vaccine.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: COVID-19 vaccine
What this could lead to: If successful, this could help doctors understand how well COVID-19 vaccines work in people with these blood cancers, guiding better vaccination strategies.
What could go wrong: This is an observational study, not a treatment trial. It only measures immune response, not whether the vaccine prevents infection. Results may not apply to all patients or vaccine types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

COVID-19 immune system disorder plasma cell myeloma Waldenstrom macroglobulinemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COVID19 IMMUNE SYSTEM DISORDER MULTIPLE MYELOMA WALDENSTROM MACROGLOBULINEMIA

Contacts and locations

Locations

Brigham and Women's Hospital

Boston, Massachusetts, 02215, United States
Dana-Farber Cancer Institute

Boston, Massachusetts, 02215, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.